Medtronic Target of Unusually High Options Trading (NYSE:MDT)

Medtronic PLC (NYSE:MDT) was the target of some unusual options trading on Thursday. Investors acquired 18,438 call options on the stock. This represents an increase of approximately 75% compared to the average daily volume of 10,557 call options.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported Q4 revenue of $9.81 billion and adjusted EPS of $1.55, both ahead of Wall Street estimates, with revenue up 9.9% year over year. Article Title
• Positive Sentiment: The company said Cardiac Ablation Solutions revenue jumped 78% globally, helping drive Medtronic’s strongest annual revenue growth in 10 years and reinforcing confidence in its growth pipeline. Article Title
• Positive Sentiment: Medtronic raised its quarterly dividend to $0.72 per share, signaling management confidence and adding support for income-focused investors. Article Title
• Neutral Sentiment: TD Cowen and RBC reiterated bullish ratings with high price targets, which supports sentiment, while multiple firms still see meaningful upside in the stock. Article Title
• Neutral Sentiment: Medtronic also submitted FDA filings to expand its Hugo robotic-assisted surgery system into more U.S. procedures, a longer-term growth catalyst for the surgical business. Article Title
• Negative Sentiment: Several firms lowered price targets, including JPMorgan, Piper Sandler, Truist, Deutsche Bank, Goldman Sachs, Wells Fargo, Leerink, and Robert W. Baird, reflecting caution around valuation and near-term outlook. Article Title
• Negative Sentiment: Medtronic’s FY2027 EPS guidance of $5.90 to $6.00 came in below the consensus estimate of $6.06, which may be limiting upside despite the strong quarter. Article Title
• Neutral Sentiment: Unusual call buying in MDT options suggests some traders are positioning for more gains after the earnings-driven rally. Article Title

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Lodestone Wealth Management LLC acquired a new position in Medtronic during the 4th quarter valued at $27,000. Anfield Capital Management LLC grew its position in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares during the last quarter. Monetary Solutions Ltd acquired a new stake in Medtronic in the 4th quarter worth $27,000. Board of the Pension Protection Fund bought a new position in shares of Medtronic during the 4th quarter worth about $29,000. Finally, GoalVest Advisory LLC acquired a new position in shares of Medtronic during the fourth quarter valued at about $29,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Up 4.1%

NYSE MDT traded up $3.20 during trading on Thursday, reaching $81.15. 7,998,631 shares of the company’s stock were exchanged, compared to its average volume of 9,133,624. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company’s fifty day simple moving average is $81.67 and its 200-day simple moving average is $92.21. The firm has a market capitalization of $104.19 billion, a PE ratio of 22.60, a P/E/G ratio of 1.76 and a beta of 0.58.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. During the same period in the prior year, the business posted $1.62 earnings per share. Medtronic’s revenue for the quarter was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Sell-side analysts predict that Medtronic will post 5.54 EPS for the current year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be paid a $0.72 dividend. The ex-dividend date is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.5%. Medtronic’s dividend payout ratio is presently 79.11%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Weiss Ratings lowered shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 21st. Leerink Partners decreased their price target on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a research report on Thursday. BTIG Research set a $90.00 price objective on Medtronic in a research report on Wednesday. Stifel Nicolaus set a $80.00 target price on Medtronic in a report on Wednesday. Finally, Needham & Company LLC cut their target price on Medtronic from $120.00 to $101.00 and set a “buy” rating on the stock in a research report on Wednesday. Sixteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $98.70.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).